

September 20, 2024

The Manager- Listing

**BSE Limited**

Corporate Relationship Dept., 5<sup>th</sup> Floor, New Trading Ring  
Rotunda Building, P J Towers, Dalal Street, Fort,  
Mumbai - 400001

The Manager- Listing

**National Stock Exchange of India Limited**

Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1, G Block  
Bandra –Kurla Complex, Bandra (E),  
Mumbai - 400051

Dear Sir(s),

**Subject: Launch of Tremelimumab (Imjudo)**

We refer to our earlier communication dated June 1, 2023, intimating the receipt of Import and Market Permission in Form CT-20 from the Drugs Controller General of India for Tremelimumab (Imjudo) Concentrate for solution for infusion 20 mg/ml (25 mg/1.25 ml and 300 mg/15 ml presentations in single dose vials) administered through intravenous route.

With regard to the same, we wish to further update that AstraZeneca Pharma India Limited will launch Tremelimumab (Imjudo) in October 2024 in India.

Tremelimumab (Imjudo) in combination with Durvalumab (Imfinzi) is indicated for the treatment of patients with unresectable hepatocellular carcinoma (uHCC).

We request you to kindly take the above on records.

Thanking You,

For **AstraZeneca Pharma India Limited**

**Manasa. R**  
**Company Secretary**